Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
stocknews6m
3 Healthcare Stocks to Watch as the Aging Population Drives Demand
As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding ...
Intermountain Medical Center first to use FDA-approved device to treat complex aortic aneurysms
Intermountain Medical Center in Murray has made medical history as the first hospital in the United States to perform a new ...
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
FDA approves 1st new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...
verywellhealth29m
FDA Clears the First Implantable Continuous Glucose Monitor That Can Last a Year
The FDA has cleared the implantable Eversense 365 CGM, which can last up to a year without replacement. The device requires ...
Medscape34m
FDA OKs First-in-Class Antipsychotic for Schizophrenia
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
BioPharma Dive42m
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
Today, a brief rundown of news from J&J and the FDA, as well as updates from Sage Therapeutics, Roche and Enanta Pharmaceuticals that you may have missed. Recent biotech company acquisitions have put ...
The American Journal of Managed Care53m
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.
92.7 WMAY56m
FDA approves first new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...